Related Experiment Videos

The proapoptotic benzodiazepine Bz-423 affects the growth and survival of malignant B cells

Anthony Boitano1, Jonathan A Ellman, Gary D Glick

  • 1Departments of Chemistry, University of Michigan, Ann Arbor, Michigan 48109, USA.

Cancer Research
|October 30, 2003
PubMed

Insights

Bz-423, a novel proapoptotic drug, effectively kills Burkitt

Area of Science:

  • Pharmacology
  • Oncology
  • Immunology

Background:

  • Bz-423 is a novel proapoptotic 1,4-benzodiazepine.
  • Previous studies demonstrated Bz-423 ameliorates disease in animal models of systemic lupus erythematosus with lymphoproliferative disease features.

Purpose of the Study:

  • To investigate the effects of Bz-423 against malignant B-cell lines derived from Burkitt's lymphoma.

Main Methods:

  • Cytotoxicity assays against various Burkitt's lymphoma B-cell lines.
  • Cell cycle analysis to determine antiproliferative effects.
  • Investigation of reactive oxygen species (ROS) and p53 involvement.
  • Assessment of binding to the peripheral benzodiazepine receptor.

Main Results:

  • Bz-423 exhibited cytotoxic activity against all tested B-cell lines, irrespective of EBV status or Bcl-2/Bcl-x(L) expression.
  • Bz-423 demonstrated potent antiproliferative activity, inducing G(1)-phase arrest independently of p53.
  • Both cytotoxicity and growth arrest were mediated by increased ROS levels and did not involve binding to the peripheral benzodiazepine receptor.

Conclusions:

  • Bz-423 possesses significant cytotoxic and antiproliferative properties against Burkitt's lymphoma B-cell lines.
  • The mechanism involves ROS generation and is independent of p53 and peripheral benzodiazepine receptor binding.
  • These findings support Bz-423's potential as an antineoplastic therapeutic agent.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...